SS 37 - H&N 1: Envisioning the Future: Leading Edge Research in HPV-Associated Oropharyngeal Cancer

Moderator(s)

• 

  Laila Gharzai, MD

  Northwestern University
  Chicago, IL
• 

  Gary Walker, MD, MS, MPH

  Banner MD Anderson Cancer Center
  Gilbert, AZ

Presentations:

• 4:00 PM – 4:10 PM ET

  Phase II Study of Radiation Volume and Dose De-Intensification Following Tors and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma - Long-Term Results of Expanded Cohort
  

  Presenter: John Lukens, MD – Hospital of the University of Pennsylvania
• 4:10 PM – 4:20 PM ET

  Quality of Life (QOL) of Patients with Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) in NRG-HN002
  

  Presenter: Minh Tam Truong, MD, MBA, MBBS, FASTRO – Boston University School of Medicine
• 4:20 PM – 4:30 PM ET

  HYHOPE: A Phase I Study of De-Intensified Hypofractionated Radiation Therapy for Human Papillomavirus-Associated Oropharynx Cancer
  

  Presenter: Dominic Moon, MD – UT Southwestern Medical Center
• 4:30 PM – 4:40 PM ET

  HPV-Seq is Prognostic in p16-Positive Oropharyngeal Cancer (OPC): Independent Validation on a Large Prospective Cohort and a Secondary Analysis of NRG-HN002
  

  Presenter: Eric Stutheit-Zhao, MD, PhD – Princess Margaret Cancer Centre
• 4:40 PM – 4:50 PM ET

  The Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamo
  

  Presenter: Li Wang, MD, PhD – MD Anderson Cancer Center
• 4:50 PM – 5:00 PM ET

  Discussant
  

  Discussant: Lachlan McDowell, PhD, MBBS, FRANZCR – Princess Alexandra Hospital